These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 26678095)
1. CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value. Pardanani A; Reichard KK; Zblewski D; Abdelrahman RA; Wassie EA; Morice Ii WG; Brooks C; Grogg KL; Hanson CA; Tefferi A; Chen D Leukemia; 2016 Apr; 30(4):914-8. PubMed ID: 26678095 [TBL] [Abstract][Full Text] [Related]
2. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Pardanani A Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695 [TBL] [Abstract][Full Text] [Related]
3. Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential pre-myelomastocytic leukemia condition. Panda D; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Sardana R; Chaturvedi A; Rajpal S; Shetty D; Patkar NV; Gujral S; Subramanian PG; Tembhare PR Cytometry B Clin Cytom; 2021 May; 100(3):331-344. PubMed ID: 32738100 [TBL] [Abstract][Full Text] [Related]
4. The Expressions of CD30 and CD123 of Mastocytosis in Taiwan. Yang CF; Hsu CY Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):278-283. PubMed ID: 35384878 [TBL] [Abstract][Full Text] [Related]
5. Mastocytosis: state of the art. Horny HP; Sotlar K; Valent P Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883 [TBL] [Abstract][Full Text] [Related]
7. Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis. Dasilva-Freire N; Mayado A; Teodosio C; Jara-Acevedo M; Álvarez-Twose I; Matito A; Sánchez-Muñoz L; Caldas C; Henriques A; Muñoz-González JI; García-Montero AC; Sánchez-Gallego JI; Escribano L; Orfao A Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30696068 [TBL] [Abstract][Full Text] [Related]
8. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980 [TBL] [Abstract][Full Text] [Related]
9. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Pardanani A Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759 [TBL] [Abstract][Full Text] [Related]
10. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. Tefferi A; Abdelmagid M; Al-Kali A; Patnaik M; Hogan WJ; Begna K; Gangat N; Orazi A; Chen D; Reichard KK; Pardanani A Am J Hematol; 2024 Jan; 99(1):21-27. PubMed ID: 37772442 [TBL] [Abstract][Full Text] [Related]
11. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815 [TBL] [Abstract][Full Text] [Related]
12. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. Pardanani A Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167 [TBL] [Abstract][Full Text] [Related]
13. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. Shah S; Pardanani A; Elala YC; Lasho TL; Patnaik MM; Reichard KK; Hanson CA; Ketterling RP; Tefferi A Am J Hematol; 2018 Dec; 93(12):1461-1466. PubMed ID: 30152525 [TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Valent P; Sotlar K; Horny HP Leuk Lymphoma; 2011 May; 52(5):740-4. PubMed ID: 21261503 [TBL] [Abstract][Full Text] [Related]
15. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ; J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094 [TBL] [Abstract][Full Text] [Related]
16. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Sotlar K; Horny HP; Simonitsch I; Krokowski M; Aichberger KJ; Mayerhofer M; Printz D; Fritsch G; Valent P Am J Surg Pathol; 2004 Oct; 28(10):1319-25. PubMed ID: 15371947 [TBL] [Abstract][Full Text] [Related]
17. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Pardanani A Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with Hwang SM; Kim BJ; Lee JS; Seong MW; Seo SH; Paik JH; Kim SA; Lee JY; Lee JO; Chang YH; Bang SM Ann Lab Med; 2022 Nov; 42(6):678-682. PubMed ID: 35765876 [TBL] [Abstract][Full Text] [Related]
20. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]